Provided by Tiger Fintech (Singapore) Pte. Ltd.

AbCellera Biologics

3.69
0.0000
Volume:1.48M
Turnover:5.45M
Market Cap:1.10B
PE:-6.40
High:3.72
Open:3.65
Low:3.54
Close:3.69
52wk High:6.52
52wk Low:1.89
Shares:299.34M
Float Shares:202.75M
Volume Ratio:0.80
T/O Rate:0.73%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.5768
EPS(LYR):-0.5533
ROE:-16.81%
ROA:-10.43%
PB:1.15
PE(LYR):-6.67

Loading ...

Prelude Therapeutics reports third quarter net loss of $19.7 million

Reuters
·
Nov 12

Stock Track | AbCellera Biologics Plunges 7.20% Following Board Reshuffle and Q3 Earnings Call

Stock Track
·
Nov 11

AbCellera Biologics’ Earnings Call: Key Insights

TIPRANKS
·
Nov 11

Stock Track | AbCellera Biologics Soars 7.03% on Board Appointment and Clinical Progress

Stock Track
·
Nov 11

AbCellera Appoints Stephen Quake to Board as Andrew Lo Resigns

Reuters
·
Nov 10

Abcellera Appoints DR. Stephen Quake to Its Board of Directors

THOMSON REUTERS
·
Nov 10

Stock Track | AbCellera Biologics Soars 5.88% Pre-market on Clinical Progress and Potential Undervaluation

Stock Track
·
Nov 10

Stock Track | AbCellera Biologics Soars 5.88% Pre-market on Clinical Progress and Undervaluation

Stock Track
·
Nov 10

AbCellera Biologics (NasdaqGS:ABCL): How Does the Latest Clinical Progress Impact Its Valuation?

Simply Wall St.
·
Nov 10

Stock Track | AbCellera Biologics Plummets 20.31% on Wider Q3 Loss and Analyst Downgrade

Stock Track
·
Nov 07

Abcellera Biologics Inc : Leerink Partners Cuts to Market Perform From Outperform; Cuts Target Price to $4 From $5

THOMSON REUTERS
·
Nov 07

Leerink Downgrades AbCellera Biologics to Market Perform From Outperform, Adjusts Price Target to $4 From $5

MT Newswires Live
·
Nov 07

Stock Track | AbCellera Biologics Plunges 9% Pre-market After Wider-Than-Expected Q3 Loss

Stock Track
·
Nov 07

Stock Track | AbCellera Biologics Surges 5.74% After Q3 Revenue Smashes Estimates

Stock Track
·
Nov 07

AbCellera Biologics Reports Q3 2025 Financial Results

TIPRANKS
·
Nov 07

AbCellera Biologics Q3 revenue smashes estimates

Reuters
·
Nov 07

BRIEF-AbCellera Q3 Revenue USD 9 Million Vs. IBES Estimate USD 5.91 Million

Reuters
·
Nov 07

Stock Track | AbCellera Biologics Plummets 5.01% Ahead of Q3 Earnings Report

Stock Track
·
Nov 07

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
Nov 06

Can AbCellera’s (ABCL) AI-Powered Discovery Platform Redefine Its Competitive Edge in Biotech?

Simply Wall St.
·
Oct 23